Exosome · Available now
Genovia™ Lactobacillus
Probiotic-enhanced exosome formulation targeting skin barrier restoration and microbiome-mediated regeneration.
Learn more →01 — Our Products
Five solutions.
One standard.
From flagship exosomes to next-generation biologics. Each formulation is patent-protected, clinician-designed, and backed by published data.
2
Available now
3
Coming soon
0%
Adverse reactions
Flagship · Available Now
Exosome Therapy
Genovia™
Next-generation exosome solution powered by patented lactoferrin-enhanced stem cell technology. 92% of patients report visible texture improvement. The new standard for regenerative aesthetics.
Technology
Lactoferrin-enhanced exosomes
Status
Available now
Recovery
3-day average downtime
For
Licensed medical professionals
Every product in the portfolio.
Available products ship to licensed medical professionals only.
Biostimulator · Coming soon
Volla™
Bio-stimulatory poly-D,L-lactic acid filler engineered for deep collagen regeneration and volumetric restoration.
Notify me when available
Topical · Coming soon
Nerv™
Advanced face mask system combining peptide age-reversal science with transdermal delivery technology.
Notify me when available
Injectable · Coming soon
Peptide
Clinical-grade peptide solutions engineered for physician-administered metabolic and aesthetic applications.
Notify me when available03 — Early Access
Three products launching soon.
Volla™, Nerv™, and Peptide are in final development. Join the waitlist and be first to order when they ship.
Volla™ (PDLLA)
Bio-stimulatory collagen filler
Q3 2026
Nerv™
Post procedure mask system
Q3 2026
Peptide
Clinical-grade injectables Made in America
Q4 2026
Takes you to our contact form. Licensed medical professionals only.
Numbers that speak for the work, not the marketing.
92%
Texture improvement
Visible skin texture improvement in Genovia™ exosome clinical studies.
3DAYS
Recovery time
Average downtime reported by Genovia™ patients across documented cases.
2×
Exosome potency
Genovia™ exosome yield versus conventional isolation methods.
0%
Adverse reactions
Adverse reaction rate in Genovia™ exosome clinical studies.
